Abstract

Objective. We examined the relationship between maternal plasma transforming growth factor-β1 (TGF-β1) concentrations and risk of preeclampsia among women delivering at Harare Maternity Hospital in Zimbabwe. We evaluated the relationship in the context of maternal systemic inflammation using plasma tumor necrosis factor-α soluble receptor p55 (sTNFp55) as a marker.Methods. 132 women with preeclampsia and 180 controls were included in this case-control study analysis. Maternal post-diagnosis plasma TGF-β1 and sTNFp55 concentrations were determined using immunoassays. Logistic regression procedures were used to estimate odds ratios (OR) and 95% confidence intervals (CI) adjusted for confounders.Results. A linear increase in preeclampsia risk was observed with increasing quartiles of TGF-β1 concentrations (p < 0.01). Women whose TGF-β1 concentrations were ⩾ 25.1 ng/ml (quartile 4) had a 2.5-fold (95% CI 1.2–5.6) increased risk of preeclampsia as compared with those women whose concentrations were < 11.2 ng/ml (quartile 1). Relative to women with no evidence of systemic inflammation and no elevated TGF-β1 concentrations, those women who were jointly positive for elevated TGF-β1 and sTNFp55 concentrations experienced a 5.3-fold (95% CI 2.3–12.0) increased risk of preeclampsia.Conclusion. Overall, we noted that elevated TGF-β1 is associated with an increased risk of preeclampsia. We also noted that the preeclampsia risk is exaggerated in the presence of maternal systemic inflammation.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call